Previous 10 | Next 10 |
Prothena (PRTA) announces that it and licensee Roche (RHHBY) will advance prasinezumab into a Phase 2b study in patients with early Parkinson's disease ((PD)). It will earn a $60M milestone payment when the first participant is dosed.In April, Roche announced that Part 1 of a Phase 2 study, P...
First anti-alpha-synuclein antibody to advance into confirmatory large study in patients with early P arkinson’s disease ; expected to initiate in 2021 Prothena to earn a $60 million clinical milestone upon first patient dosed ...
Quick Take Inhibikase Therapeutics ( IKT ) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for neurodegenerative and cancer diseases. IKT is still at a ...
DUBLIN, Ireland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases will hold an investo...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead A full slate of investor conferences and updates in the week ahead will include presentations by e...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Volatility watch: Cinemark (NYSE: CNK ) and On Semiconductor (NASDAQ: ON ) have both seen sizable jumps in short interest positions, while the daily swings in Stitch Fix (NASDAQ: SFIX ) could to get large amid a high level of short interest even as Wall Street firms turn bullish. Op...
First potentially disease-modifying, anti-alpha-synuclein antibody to demonstrate signals of efficacy on multiple pre-specified secondary and exploratory clinical endpoints, including measures of motor function and biomarkers, in patients with early Parkinson’s disease Signifi...
DUBLIN, Ireland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that m...
DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced upd...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...